CN101474166B - Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof - Google Patents
Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof Download PDFInfo
- Publication number
- CN101474166B CN101474166B CN2009100141174A CN200910014117A CN101474166B CN 101474166 B CN101474166 B CN 101474166B CN 2009100141174 A CN2009100141174 A CN 2009100141174A CN 200910014117 A CN200910014117 A CN 200910014117A CN 101474166 B CN101474166 B CN 101474166B
- Authority
- CN
- China
- Prior art keywords
- hydrochloride
- pseudoephedrine
- piller
- cetirizine
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a cetirizine pseudoephedrine slow release capsule. Cetirizine hydrochloride is prepared to quick release pellets and pseudoephedrine hydrochloride is prepared to slow release pellets, in accordance with the weight proportion that each 1000 preparations contain 5g of cetirizine hydrochloride and 120g of pseudoephedrine hydrochloride, the two pellets are uniformly mixed and encapsulated; or the two pellets are encapsulated respectively in proportion. The quick release part of the cetirizine hydrochloride and the slow release part of the pseudoephedrine hydrochloride are synthesized together subsequent to being prepared to the pellets respectively, so as to prepare the capsule with two different medicine-releasing speeds, the medicine-releasing speed of each pellet is uniform and the medicine effect is steady. The capsule has the advantages of even and extensive distribution of the medicine in vivo subsequent to the administering, sufficient absorption of the medicine, small stimulation to gastrointestinal tracts and good reproducibility of the medicine-releasing rule, and improves, while maintaining the properties of rapid effecting and long half-life of the cetirizine, the pharmacokinetic properties of the pseudoephedrine hydrochloride to administer twice per day instead of having to administer four times per day, so that both reach the optimal cooperative curative effect.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, a kind of cetirizine pseudoephedrine sustained-release capsules of specifically forming and preparation method thereof by cetirizine hydrochloride quick releasing formulation and pseudoephedrine hydrochloride slow release preparation.
Background technology
According to statistics; About 59% crowd suffers from seasonal and perennial anaphylaxis; Wherein 30% with nasal congestion, and inducement is often owing to when being exposed in the allergen, can causing producing specific IgE antibody and be attached on the pillar cells and the basophilic leukocyte receptor; And then cause that histamine and other inflammatory mediator discharge, and have produced direct or early stage anaphylaxis from the pillar cells and basophil.And allergic rhinitis is exactly a kind of more common seasonality or the disease of chronicity; Its clinical symptoms comprises nasal congestion, airflow obstruction; Rhinorrhea, sneeze, the other pain of pruritus, nose and headache, anosmia or obstacle, chronic pharyngitis, nasal cavity or the nasal sinuses recurrent infection of nose and eye.The preventive measure of a common line is the oral antihistamines thing and avoid contacting allergen.It is oral that to separate congested agent also be the effective ways that are used for effectively alleviating the nasal congestion of Allergic Rhinitis.
From first antihistaminic exploitation of nineteen thirty-seven so far, kind of H surplus oneself has 50
1Receptor antagonist supplies clinical use.First generation medicine before the eighties comprises diphenhydramine, chlorine Ben Namin, promethazine etc., and receptor-specific is poor, and the nervus centralis activity is stronger, can cause tangible calmness and cholinolytic effect, so be called as calmness property antihistaminic; So far the second filial generation antihistaminic of developing the eighties comprises terfenadine, astemizole, loratadine, cetirizine etc., H
1Receptor-selective is high, no sedation, and central nervous system's untoward reaction is less, so be called non-sedative antihistamine medicine (NSA).These medicines particularly terfenadine and astemizole can bring out cardiac toxicity, though incidence rate is very low, consequence is serious, mainly can cause various arrhythmia, and wherein the most serious is torsade de pointes, claims the lethal arrhythmia again.Therefore in aforementioned four kinds of medicines, the use of terfenadine and astemizole is restricted, and the former stops using and produce in many countries, and the latter stops using in the U.S..Loratadine and cetirizine receive an acclaim because of cardiac toxicity is less, become the maximum antihistaminic of sales volume in the world wide.
Cetirizine is compared with other antihistaminics, and it is to periphery H
1Receptor has stronger selectivity; But the not only effect of the early stage histamine of antagonism allergy; The chemotactic response that also can suppress allergy related inflammation in late period cell clinically is usually used in treating anaphylactic diseases such as all kinds urticaria, allergic rhinitis, pollinosis, anaphylaxis conjunctivitis, asthma.There are not side effect such as tangible calmness and cholinolytic under the common dose.The pharmacological action that it is unique promptly removes and blocks H in early days in anaphylaxis
1Outside the receptor, the eosinophilic granulocyte who also the anaphylaxis later stage is played an important role has powerful inhibitory action, so the antiallergic drug effect is better than other all antihistaminics.
Patient is when existing the multiple symptom of allergic rhinitis, and it is more reasonable that antihistaminic and long-acting adrenergic agonist share, and pseudoephedrine hydrochloride is the epimer of ephedrine; Clinical used be hydrochloric acid dextrorotation pseudoephedrine; The alternative upper respiratory tract blood vessel that shrinks is eliminated the nasal mucosa edema, and a little less than the influence to whole body blood vessel and blood pressure; With the antihistaminic compatibility; Can be used for treating the nasal congestion symptom that flu, allergic rhinitis, rhinitis and sinusitis cause, most of patients is better to the drug combination tolerance, and obvious adverse reaction is not found in clinical observation.
Between pseudoephedrine hydrochloride and the second filial generation antihistaminic collaborative, booster action is arranged, can obviously eliminate flu and upper respiratory tract allergic symptom.In the antiallergic agent field, treat with cetirizine hydrochloride, pseudoephedrine hydrochloride compound formulation at present, clinical boundary obtains certainly in the world.This associating operational version every day 2 times, can effectively alleviate the allergic rhinitis symptom, especially to the patient of obvious nasal obstruction is arranged, give patient best treatment.And the data of announcing according to Pfizer, these article treat anaphylactic disease widely aspect and like product Claritin-D
12Hour, Claritin-D24Hour, Allegra-D compare, and curative effect is sure.
Chinese patent 02145079.X discloses a kind of " containing preparation of cetirizine hydrochloride and pseudoephedrine hydrochloride and preparation method thereof " is the inner layer piece with the outer-skin sheet parcel pseudoephedrine hydrochloride of cetirizine hydrochloride.Though solved the problem of cetirizine rapid release and pseudoephedrine hydrochloride slow release, the ectonexine tablet can not discharge drug effect simultaneously.One Chinese patent application numbers 200710179843.2 discloses a kind of " cetirizine pseudoephedrine sustained-release capsules " technology, is earlier cetirizine hydrochloride to be processed the rapid release microplate; Pseudoephedrine hydrochloride is processed the slow release microplate, in two kinds of microplates being incapsulated by proportioning, though two kinds of medicines can discharge drug effect simultaneously again; But the volume of two kinds of microplates is all bigger, out-of-shape; Be inconvenient to fill, cause drug release inhomogeneous easily, drug effect is unstable; This processes is complicated in addition, and the process-cycle is long.
Summary of the invention
The present invention lumps together the immediate release section of cetirizine hydrochloride and the slow-released part of pseudoephedrine hydrochloride in order to overcome the defective in the above-mentioned technology, keep the cetirizine hydrochloride onset rapidly, in the long half time; The medicine that improves the pseudoephedrine hydrochloride administration is for characteristic; Process and have two kinds of different drug release rates, the uniform capsule of drug release makes both reach the optimum synergistic curative effect; Be evenly distributed in vivo, extensively; Absorb fully, GI irritation is little, a kind of cetirizine pseudoephedrine sustained-release capsules of release rule favorable reproducibility and this capsular method for preparing thereof.
Technical problem of the present invention is realized by following technical scheme: a kind of cetirizine pseudoephedrine sustained-release capsules; Cetirizine hydrochloride is processed release pills; Pseudoephedrine hydrochloride is processed slow-release pill; By the hydrochloric cetirizine 5g of per 1000 preparations, the weight proportion of pseudoephedrine hydrochloride 120g is made by following method for preparing:
The preparation of pseudoephedrine hydrochloride piller: (1000)
(1) weight proportion of the plain ball of pseudoephedrine hydrochloride:
Pseudoephedrine hydrochloride 120g
Dextrin 25g
Blank pill heart 30g
Water 50g
(2) weight proportion of pseudoephedrine hydrochloride piller coating:
The plain ball 175g of pseudoephedrine hydrochloride
Sulisi (solids content 25%) 35～140g
Water 23～93g
(3) preparation technology:
The preparation of pseudoephedrine hydrochloride slow release piller: (1000)
With pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride; After the drying, the Sulisi coating solution with 15% carries out coating, makes the pseudoephedrine hydrochloride slow release piller;
The preparation of cetirizine hydrochloride piller: (1000)
(1) weight proportion of the plain ball of cetirizine hydrochloride:
Cetirizine hydrochloride 5g
Dextrin 30g
Blank pill heart 15g
50% ethanol 20g
(2) weight proportion of cetirizine hydrochloride piller coating:
The plain ball 50g of cetirizine hydrochloride
Opadry 1.5g
Water 8.5g
(3) preparation technology:
Material behind cetirizine hydrochloride and the abundant mix homogeneously of dextrin is wrapping on the blank pill heart; Be prepared into the pastille piller of cetirizine hydrochloride, place 60 ℃ of baking oven dryings after, be made into 15% Opadry coating solution; Cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan; Adopt bottom spraying type coating mode, the Opadry coating solution with 15% carries out coating, promptly obtains the cetirizine hydrochloride release pills;
Above-mentioned two kinds of pillers are mixed in proportion, adopt capsule filling machine once to adorn capsule, also can two kinds of pillers be adorned capsule respectively with the capsule filling machine with secondary filling function.
By in per 1000 preparations, the preferred content of Sulisi is 70g in the pseudoephedrine hydrochloride piller coating, and the preferred content of water is 47g.
The dose of preparation of the present invention is composed of multiple units. and compare with single dose dosage form (conventional tablet or capsule etc.), have many advantages: can improve medicine and gastrointestinal contact area, make drug absorption complete, thereby improve bioavailability; The piller combination of different rate of releasing drug can obtain ideal rate of releasing drug, obtains the blood drug level of expection, and can keep long action time, avoids the untoward reaction such as stimulation to gastric mucosa; Owing to its drug release behavior is a summation of forming a plurality of piller drug release behaviors of a dosage, the drug release behavior generation that the defective in therefore indivedual pillers preparations is unlikely total formulation has a strong impact on, and its release rule has repeatability; Medicine seldom receives the influence that gastric emptying changes in vivo, and absorption in vivo also has good repeatability; Can increase stability of drug. and also be convenient to quality control.
A kind of compound recipe west is the weight proportion according to claim 1 or 2 for the capsular method for preparing of pseudoephedrine release, is made by following method for preparing:
(1) with pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin, then with the blank pill heart insert multifunctional fluidized bed in, keeping under the state of multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride; The pastille piller places 60 ℃ of baking ovens dry; After the drying, place multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode; Sulisi coating solution with 15% carries out coating, and coating promptly obtains the pseudoephedrine hydrochloride slow release piller after finishing;
(2) with cetirizine hydrochloride and the abundant mix homogeneously of dextrin, then with the blank pill heart insert multifunctional fluidized bed in, keeping under the state of multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in; Be wrapping on the blank pill heart, be prepared into the pastille piller of cetirizine hydrochloride, the pastille piller places 60 ℃ of baking ovens dry; Opadry is added to the water in the process that constantly stirs; Be made into 15% Opadry coating solution, cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode; Opadry coating solution with 15% carries out coating, and coating promptly obtains the cetirizine hydrochloride release pills after finishing;
(3) by hydrochloric pseudoephedrine piller: 0.184～0.210g in every capsules; The weight proportion of cetirizine hydrochloride piller: 0.052g calculates loading amount respectively, according to the loading amount ratio that calculates; With two kinds of piller mix homogeneously; Adopt capsule filling machine once to adorn capsule, also can adorn capsule respectively with capsule filling machine with two kinds of pillers according to the loading amount ratio that calculates with secondary filling function.
Preferable methods is: in per 1000 preparations; Two kinds of pillers are pressed hydrochloric pseudoephedrine piller: 0.193g in every capsules; The mixed of cetirizine hydrochloride piller: 0.052g is even; Adopt capsule filling machine once to adorn capsule, or two kinds of pillers are adorned capsule respectively with the capsule filling machine with secondary filling function.
Advantage of the present invention is: after the immediate release section of cetirizine hydrochloride and the slow-released part of pseudoephedrine hydrochloride are processed piller respectively, lump together, process the capsule with two kinds of different drug release rates; The release homogeneous of each piller, efficacy stability has and takes the back medicine and be evenly distributed in vivo, extensively; Absorb fully, GI irritation is little, the advantage of release rule favorable reproducibility; Keep the cetirizine hydrochloride onset rapidly, in the long half time; The medicine that has improved necessary 4 administrations on the one of pseudoephedrine hydrochloride is for characteristic, and 2 administrations on the one make both reach the optimum synergistic curative effect.
The specific embodiment
Embodiment 1
1. contain the following plain ball of weight proportion elder generation salt manufacturing acid pseudoephedrine by per 1000:
Pseudoephedrine hydrochloride 120g
Dextrin 25g
Blank pill heart 30g
Water 50g
With pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride.
Contain following weight proportion salt manufacturing acid pseudoephedrine piller coating by per 1000:
The plain ball 175g of pseudoephedrine hydrochloride
Sulisi (solids content 25%) 35g
Water 23g
Place 60 ℃ of baking ovens dry the pastille piller, after the drying, place multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Sulisi coating solution with 15% carries out coating.Coating promptly obtains the pseudoephedrine hydrochloride slow release piller after finishing.
2. contain the following plain ball of weight proportion salt manufacturing acid cetirizine by per 1000:
Cetirizine hydrochloride 5g
Dextrin 30g
Blank pill heart 15g
50% ethanol 20g
With cetirizine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of cetirizine hydrochloride.
Contain following weight proportion salt manufacturing acid cetirizine piller coating by per 1000:
The plain ball 50g of cetirizine hydrochloride
Opadry 1.5g
Water 8.5g
Place 60 ℃ of baking ovens dry the pastille piller; Opadry is added to the water in the process that constantly stirs; Be made into 15% Opadry coating solution; Cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Opadry coating solution with 15% carries out coating.Coating promptly obtains the cetirizine hydrochloride release pills after finishing.
3. piller is adorned capsule technology:
By hydrochloric pseudoephedrine piller: 0.186g in every capsules, the mixed of cetirizine hydrochloride piller: 0.052g is even with two kinds of pillers, and two kinds of pillers are adorned capsule respectively with the capsule filling machine with secondary filling function.
Embodiment 2
1. contain the following plain ball of weight proportion elder generation salt manufacturing acid pseudoephedrine by per 1000:
Pseudoephedrine hydrochloride 120g
Dextrin 25g
Blank pill heart 30g
Water 50g
With pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride.
Contain following weight proportion salt manufacturing acid pseudoephedrine piller coating by per 1000:
The plain ball 175g of pseudoephedrine hydrochloride
Sulisi (solids content 25%) 70g
Water 46g
Place 60 ℃ of baking ovens dry the pastille piller, after the drying, place multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Sulisi coating solution with 15% carries out coating.Coating promptly obtains the pseudoephedrine hydrochloride slow release piller after finishing.
2. contain the following plain ball of weight proportion salt manufacturing acid cetirizine by per 1000:
Cetirizine hydrochloride 5g
Dextrin 30g
Blank pill heart 15g
50% ethanol 20g
With cetirizine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of cetirizine hydrochloride.
Contain following weight proportion salt manufacturing acid cetirizine piller coating by per 1000:
The plain ball 50g of cetirizine hydrochloride
Opadry 1.5g
Water 8.5g
Place 60 ℃ of baking ovens dry the pastille piller; Opadry is added to the water in the process that constantly stirs; Be made into 15% Opadry coating solution; Cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Opadry coating solution with 15% carries out coating.Coating promptly obtains the cetirizine hydrochloride release pills after finishing.
3. piller is adorned capsule technology:
By the hydrochloric pseudoephedrine 120g of per 1000 preparations, the weight proportion mixed of cetirizine hydrochloride 5g is even with two kinds of pillers, adopts capsule filling machine once to adorn capsule.
Embodiment 3
1. contain the following plain ball of weight proportion elder generation salt manufacturing acid pseudoephedrine by per 1000:
Pseudoephedrine hydrochloride 120g
Dextrin 25g
Blank pill heart 30g
Water 50g
With pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride.
Contain following weight proportion salt manufacturing acid pseudoephedrine piller coating by per 1000:
The plain ball 175g of pseudoephedrine hydrochloride
Sulisi (solids content 25%) 140g
Water 93g
Place 60 ℃ of baking ovens dry the pastille piller, after the drying, place multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Sulisi coating solution with 15% carries out coating.Coating promptly obtains the pseudoephedrine hydrochloride slow release piller after finishing.
2. contain the following plain ball of weight proportion salt manufacturing acid cetirizine by per 1000:
Cetirizine hydrochloride 5g
Dextrin 30g
Blank pill heart 15g
50% ethanol 20g
With cetirizine hydrochloride and the abundant mix homogeneously of dextrin; Then with the blank pill heart insert multifunctional fluidized bed in; Under the state that keeps multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of cetirizine hydrochloride.
Contain following weight proportion salt manufacturing acid cetirizine piller coating by per 1000:
The plain ball 50g of cetirizine hydrochloride
Opadry 1.5g
Water 8.5g
Place 60 ℃ of baking ovens dry the pastille piller; Opadry is added to the water in the process that constantly stirs; Be made into 15% Opadry coating solution; Cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode, the Opadry coating solution with 15% carries out coating.Coating promptly obtains the cetirizine hydrochloride release pills after finishing.
3. piller is adorned capsule technology:
By hydrochloric pseudoephedrine piller: 0.210g in every capsules, the mixed of cetirizine piller: 0.052g is even with two kinds of pillers, adopts capsule filling machine once to adorn capsule.
Quality examination:
West piperazine pseudoephedrine release capsule drug release determination result:
West piperazine pseudoephedrine release capsule content is measured
West piperazine pseudoephedrine release capsule content is measured the result
Claims (1)
1. a compound recipe west is for the pseudoephedrine release capsule; It is characterized in that: cetirizine hydrochloride is processed release pills; Pseudoephedrine hydrochloride is processed slow-release pill, and by the hydrochloric pseudoephedrine 120g of per 1000 preparations, the weight proportion of cetirizine hydrochloride 5g is made by following method for preparing:
The preparation of pseudoephedrine hydrochloride piller: by 1000
(1) weight proportion of the plain ball of pseudoephedrine hydrochloride:
(2) weight proportion of pseudoephedrine hydrochloride piller coating:
The plain ball 175g of pseudoephedrine hydrochloride
Solids content is 25% Sulisi 35g or 70g
Water 23g or 46g
(3) preparation technology:
The preparation of pseudoephedrine hydrochloride slow release piller: by 1000
With pseudoephedrine hydrochloride and the abundant mix homogeneously of dextrin, then with the blank pill heart insert multifunctional fluidized bed in, keeping under the state of multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in, be wrapping on the blank pill heart, be prepared into the pastille piller of pseudoephedrine hydrochloride; The pastille piller places 60 ℃ of baking ovens dry; After the drying, place multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode; Sulisi coating solution with 15% carries out coating, and coating promptly obtains the pseudoephedrine hydrochloride slow release piller after finishing;
The preparation of cetirizine hydrochloride piller: by 1000
(1) weight proportion of the plain ball of cetirizine hydrochloride:
(2) weight proportion of cetirizine hydrochloride piller coating:
The plain ball 50g of cetirizine hydrochloride
Opadry 1.5g
Water 8.5g
(3) preparation technology:
With cetirizine hydrochloride and the abundant mix homogeneously of dextrin, then with the blank pill heart insert multifunctional fluidized bed in, keeping under the state of multifunctional fluidized bed rotation; With the material behind the mix homogeneously under the moistening of water, progressively join multifunctional fluidized bed in; Be wrapping on the blank pill heart, be prepared into the pastille piller of cetirizine hydrochloride, the pastille piller places 60 ℃ of baking ovens dry; Opadry is added to the water in the process that constantly stirs; Be made into 15% Opadry coating solution, cetirizine hydrochloride piller after the drying is placed multifunctional fluidized bed coating pan, adopt bottom spraying type coating mode; Opadry coating solution with 15% carries out coating, and coating promptly obtains the cetirizine hydrochloride release pills after finishing;
With two kinds of pillers by hydrochloric pseudoephedrine piller in every capsules: 0.184 or 0.193g, the mixed of cetirizine hydrochloride piller: 0.052g is even, and two kinds of pillers are filled the capsule filling machine of function and adorned capsule respectively with having secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100141174A CN101474166B (en) | 2009-01-22 | 2009-01-22 | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100141174A CN101474166B (en) | 2009-01-22 | 2009-01-22 | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101474166A CN101474166A (en) | 2009-07-08 |
| CN101474166B true CN101474166B (en) | 2012-06-20 |
Family
ID=40835013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100141174A Expired - Fee Related CN101474166B (en) | 2009-01-22 | 2009-01-22 | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101474166B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103340865A (en) * | 2013-07-08 | 2013-10-09 | 广东彼迪药业有限公司 | Cetirizine hydrochloride tablet and preparation method thereof |
| CN104758180A (en) * | 2014-01-06 | 2015-07-08 | 山东诚创医药技术开发有限公司 | Secondary filling method for compound preparation capsules |
| CN104490880A (en) * | 2014-11-21 | 2015-04-08 | 哈尔滨圣吉药业股份有限公司 | Cetirizine hydrochloride pseudo ephedrine sustained-release pellet and preparation method thereof |
| CN104800178B (en) * | 2015-05-18 | 2017-09-01 | 张祥坤 | A kind of Cetirizine hydrochloride tablet and preparation method thereof |
-
2009
- 2009-01-22 CN CN2009100141174A patent/CN101474166B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101474166A (en) | 2009-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105142618A (en) | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| TW200427450A (en) | Pharmaceutical composition comprising histamine H3 receptor antagonist providing nasal decongestant effect | |
| CN101474166B (en) | Cetirizine and pseudoephedrine sustained-release capsule and preparation method thereof | |
| CN104840443A (en) | Medicine composition containing active ingredients of pregabalin | |
| KR102444494B1 (en) | Compositions and methods for treatment of abnormal cell growth | |
| KR101587140B1 (en) | Capsule containing mini-tablets comprising mosapride citrate for sustained-releasing formulation improving gastrointestinal disease and preparing the method thereof | |
| CN109646417A (en) | A kind of Trimetazidine sustained release tablets and preparation method thereof | |
| CN102772392B (en) | Arbidol sustained or controlled release capsule and preparation method thereof | |
| CN106924205A (en) | A kind of sustained release preparation containing Baricitinib | |
| CN105434398A (en) | Rabeprazole enteric-coated micro pellet, and preparation method thereof | |
| CN101524355A (en) | Compound preparation of antituberculosis medicaments, and preparation method thereof | |
| CN106806353B (en) | Iguratimod sustained-release capsule and preparation method thereof | |
| CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
| CN101422441B (en) | Nimesulide sustained-release tablet and preparation method thereof | |
| CN1857265A (en) | Slow released omeprazole/domperidone preparation and its preparing process and application | |
| CN102579403B (en) | Duloxetine hydrochloride drug composition | |
| CN103271907B (en) | Oral medicine composition consisting of berberine and melbine, and preparation method thereof | |
| CN107441051A (en) | A kind of propafenone hydrochloride microplate and preparation method thereof | |
| CN101168059A (en) | Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof | |
| CN104127390B (en) | A kind of Domperidone Tablets and preparation technology thereof | |
| CN104382882A (en) | PH-independent zaleplon dipulse release capsule and method for preparing same | |
| CN106176761B (en) | Application of composition containing isosorbide mononitrate and ivabradine | |
| CN103230379A (en) | Orally disintegrating sustained-release preparation containing tamsulosin hydrochloride and preparation method thereof | |
| CN102600108A (en) | Flurbiprofen sustained release capsules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120620 Termination date: 20160122 |
|
| EXPY | Termination of patent right or utility model |